In closing, our data support the testing of ULK1/2 inhibitors in patients with KRAS-driven lung cancer, either as single agents or in combination with direct inhibitors of KRAS oncoproteins, or of KRAS-regulated signaling pathways downstream of KRAS such as the RAF>MEK>ERK MAP kinase pathway. This evidence concerns the gene ULK1 and lung carcinoma.